Key terms
About SYBX
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SYBX news
Mar 21
5:23pm ET
Synlogic Appoints James Flynn to Board Amidst Director Resignations
Mar 21
2:18am ET
Hold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic Uncertainties
Mar 20
11:35am ET
H.C. Wainwright upgrades Synlogic (SYBX) to a Hold
Mar 20
11:30am ET
Synlogic upgraded to Neutral from Sell at H.C. Wainwright
Mar 20
11:29am ET
Synlogic upgraded to Neutral from Sell at H.C. Wainwright
Mar 19
7:02am ET
Synlogic reports Q4 EPS ($1.71), consensus (97c)
Feb 22
4:54pm ET
Synlogic Announces Top Executive Departures and Compensation Deals
Feb 20
4:26pm ET
Synlogic Enacts Shareholder Rights Plan for Equitable Control
Feb 20
12:22pm ET
Synlogic approves shareholder rights plan, authorizes dividend distribution
Feb 20
12:19pm ET
Synlogic engaged Ladenburg to assist in strategic review
Feb 13
5:13am ET
Hold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price Target
Feb 12
4:14pm ET
Synlogic Announces Major Restructuring and Leadership Changes
Feb 12
11:09am ET
Biotech Alert: Searches spiking for these stocks today
Feb 09
9:41am ET
PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls
Feb 09
7:49am ET
Synlogic downgraded to Neutral from Buy at Chardan
Feb 09
6:17am ET
Synlogic (SYBX) was downgraded to a Sell Rating at H.C. Wainwright
Feb 09
6:10am ET
Synlogic downgraded to Sell from Buy at H.C. Wainwright
Feb 09
6:09am ET
Synlogic downgraded to Market Perform from Outperform at Leerink
Feb 08
4:46pm ET
Synlogic sinks 52% to $1.67 after ending study and operations
Feb 08
4:45pm ET
Synlogic trading resumes
Feb 08
4:43pm ET
Synlogic to cease operations, reduce workforce by over 90%
Feb 08
4:41pm ET
Synlogic ends Synpheny-3 study, to evaluate strategic options
Feb 08
4:34pm ET
Synlogic to cease ops, reduce workforce by 90% after Synpheny-3 dicontinuation
Feb 08
4:30pm ET
Synlogic to resume trading at 4:45 pm ET
Feb 08
4:28pm ET
Synlogic to discontinue Synpheny-3 study, evaluate strategic options
Feb 08
4:13pm ET
Synlogic trading halted, news pending
Feb 02
12:03pm ET
Synlogic reports publication of prelinical, clinical data for SYNB1353
Jan 09
1:01am ET
Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)
Jan 05
6:26am ET
Optimistic Outlook for Synlogic’s Growth Potential and Financial Sustainability
Jan 04
7:04am ET
Synlogic provides corporate update, outlook for 2024
Dec 27
7:03am ET
Synlogic awarded $1M subcontract with Air Force Research Lab
No recent news articles are available for SYBX
No recent press releases are available for SYBX
SYBX Financials
Key terms
Ad Feedback
SYBX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SYBX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
